Last updated: September 17, 2026
EPANED KIT is a pediatric-oriented presentation of enalapril maleate oral solution, generally supplied as a 1 mg/mL liquid with an oral dosing device. Its commercial value comes from improving administration and dosing accuracy for children and patients unable to swallow tablets, not from a new active pharmaceutical ingredient. The product operates in a small specialty market shaped by pediatric cardiology, heart failure treatment, hospital discharge prescribing, compounding avoidance, and caregiver convenience.
Public sources do not disclose product-level revenue, unit volume, gross margin, or forecast data for EPANED KIT. The financial trajectory is therefore best assessed through product positioning, market access, competing formulations, regulatory status, and the absence of a durable active-ingredient patent barrier.
What is EPANED KIT and who markets it?
EPANED is an oral solution containing enalapril maleate, an angiotensin-converting enzyme inhibitor. Enalapril is converted in vivo to enalaprilat, which reduces angiotensin II formation and lowers blood pressure. The product is prescribed primarily when an oral liquid is clinically or practically preferable to tablets.
| Product attribute |
EPANED |
| Active ingredient |
Enalapril maleate |
| Dosage form |
Oral solution |
| Strength |
1 mg/mL |
| Primary use |
Hypertension and cardiovascular treatment requiring enalapril |
| Patient segment |
Pediatric and swallowing-impaired patients |
| Regulatory pathway |
FDA-approved prescription drug |
| Original product company |
Silvergate Pharmaceuticals |
| Current commercial context |
Specialty pediatric and liquid-dose market |
| Competitive substitutes |
Enalapril tablets, pharmacy-compounded liquids, lisinopril oral solution, captopril liquids |
The "kit" designation generally relates to the commercial package and dosing components rather than a separate active ingredient or new pharmacologic product. FDA labeling identifies EPANED as a prescription oral solution and provides dosing and administration instructions for the liquid presentation. [1]
Silvergate built its portfolio around liquid formulations of established drugs. The company was later acquired by or integrated into Azurity Pharmaceuticals, a specialty pharmaceutical company focused on patient-friendly dosage forms. The ownership and commercialization history matters because EPANED is positioned within a broader specialty-formulation portfolio rather than as a mass-market primary-care product.
What market need does EPANED address?
EPANED addresses three recurring problems associated with solid oral dosage forms:
- Children may be unable to swallow tablets.
- Extemporaneous compounding can produce concentration, stability, flavor, and measurement variability.
- Caregivers and clinicians need a commercially manufactured liquid with a calibrated administration device.
The relevant market is narrower than the overall enalapril market. Generic enalapril tablets are widely available at low prices, while EPANED competes for patients for whom the liquid formulation has practical or clinical value.
Demand is concentrated in:
- Pediatric cardiology and nephrology
- Congenital heart disease
- Pediatric hypertension
- Heart failure management
- Post-discharge medication programs
- Patients with feeding tubes or dysphagia
- Institutional and specialty pharmacy channels
The product’s addressable population is limited, but the liquid dosage form can support a price premium over generic tablets. That premium depends on payer coverage, formulary status, pharmacy availability, and the cost of substituting a compounded preparation.
How large is the EPANED market?
EPANED’s market is a specialty niche rather than a high-volume cardiovascular franchise. Enalapril is a mature molecule with extensive generic competition. The product’s growth is therefore constrained by the size of the liquid-dose segment and by substitution from compounded products.
The primary market drivers are:
| Driver |
Effect on EPANED |
| Pediatric cardiovascular prescribing |
Supports demand |
| Greater recognition of medication errors in liquid dosing |
Supports branded liquid use |
| Hospital discharge protocols |
Can increase repeat prescriptions |
| Pharmacy compounding capacity |
Creates substitution pressure |
| Generic tablet pricing |
Limits willingness to pay |
| Payer restrictions |
Can reduce conversion |
| Oral-solution shortages or supply disruptions |
Can produce temporary volume shifts |
| Specialty pharmacy distribution |
Supports access but adds channel complexity |
A key commercial advantage is the ability to offer a standardized concentration. A 1 mg/mL solution reduces the calculation burden associated with converting a tablet into a compounded suspension. That advantage is most relevant when patients require individualized doses or cannot tolerate solid formulations.
The central market constraint is that many pharmacies can compound enalapril liquids when a commercial product is unavailable or not covered. Compounding gives prescribers and pharmacists an alternative, although the alternative may have different stability, flavor, documentation, and quality-control characteristics.
What is the FDA regulatory status of EPANED?
EPANED was approved by the FDA as an oral solution of enalapril maleate under NDA 207985. The product is regulated as a prescription drug, and its label includes adult and pediatric dosing information, contraindications, warnings, and administration instructions. [1]
The principal safety issues are consistent with the enalapril class:
- Fetal toxicity during pregnancy
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Interaction with sacubitril/valsartan
- Contraindication with aliskiren in patients with diabetes
- Potential renal effects in susceptible patients
The solution contains excipients that are relevant to pediatric use and administration. Prescribers and pharmacists must account for dose measurement, storage, handling, and the patient’s ability to tolerate the formulation.
FDA approval of a liquid presentation does not eliminate competition from tablets or compounded products. It establishes regulatory validation for the specific formulation and labeling, but it does not create exclusivity over enalapril therapy generally.
What patents protect EPANED KIT?
The core enalapril active-ingredient patents are long expired. EPANED’s commercial protection, if any, would depend primarily on formulation patents, manufacturing know-how, regulatory exclusivity, trademarks, and distribution execution.
| Protection category |
EPANED position |
| Active-ingredient patent |
Expired for the mature enalapril molecule |
| Tablet composition patents |
Not directly relevant to the oral-solution kit |
| Oral-solution formulation patents |
Potentially relevant, but no durable broad barrier is established in the public commercial profile |
| Method-of-use patents |
Limited strategic value because enalapril uses are long established |
| FDA exclusivity |
Any initial approval-related exclusivity would have been time-limited |
| Trademark |
Protects the EPANED brand, not enalapril therapy |
| Manufacturing know-how |
May create practical barriers without blocking alternative formulations |
| Regulatory filing |
Protects the approved product dossier against certain approval pathways for a defined period |
The most important distinction is between a formulation patent and a broad market patent. A patent covering a specific concentration, excipient combination, stability profile, or manufacturing process may complicate direct copying of the branded liquid. It does not prevent generic enalapril tablets, pharmacy compounding, or competing liquid ACE inhibitors.
The FDA Orange Book should be used to confirm current patent listings and exclusivity codes for NDA 207985. The commercial record does not indicate that EPANED has a current patent position comparable to a protected new chemical entity. [2]
When does EPANED lose exclusivity?
EPANED’s commercial exclusivity is materially different from the exclusivity of a novel drug.
Enalapril’s underlying molecule is generic and broadly available. Any regulatory exclusivity tied to the approval of a new liquid formulation would have been limited in duration and would not prevent use of enalapril tablets or extemporaneous liquids. The product’s long-term protection is therefore based on brand recognition, physician familiarity, supply reliability, formulation performance, and payer access.
Exclusivity timeline
| Event |
Commercial implication |
| Original enalapril approval |
Established the active ingredient and therapeutic class |
| EPANED NDA approval |
Created an FDA-approved oral-solution product |
| Initial regulatory exclusivity period |
Temporarily limited certain competing approvals, if applicable |
| Expiration of initial exclusivity |
Opened the market to additional regulatory competition where filings were available |
| Mature branded-liquid phase |
Shifted value toward formulation execution and channel access |
There is no biosimilar risk. EPANED is a small-molecule drug, not a biologic. The relevant competitive threats are generic oral solutions, authorized alternatives, compounded preparations, and other liquid ACE inhibitors.
Are there Paragraph IV challenges to EPANED?
No major publicly visible Paragraph IV litigation has established a meaningful challenge to EPANED’s commercial position. That outcome is consistent with the product’s limited market size and the difficulty of generating attractive returns from a niche oral liquid containing a mature generic molecule.
A Paragraph IV challenge would be commercially rational only if:
- EPANED had an enforceable formulation patent listed in the Orange Book;
- Annual sales supported the cost of litigation and launch preparation;
- The challenger could reproduce the formulation at a lower cost;
- Payers and prescribers would accept substitution;
- Manufacturing and stability requirements were manageable.
For this type of product, a competitor may choose an alternative regulatory strategy, such as an abbreviated application or a different formulation, rather than litigate a narrow formulation patent. The absence of prominent litigation does not prove that no patent exists. It indicates that the publicly observable litigation risk has not become a major market event.
How does EPANED compare with competing drugs?
EPANED competes against both direct and indirect alternatives.
| Product or alternative |
Competitive relationship |
| Generic enalapril tablets |
Lowest-cost substitute when swallowing is possible |
| Compounded enalapril liquid |
Direct substitute with variable formulation characteristics |
| Qbrelis, lisinopril oral solution |
Approved liquid ACE-inhibitor alternative |
| Captopril compounded liquid |
Alternative ACE inhibitor, often used in pediatric settings |
| Losartan liquid formulations |
Alternative renin-angiotensin system therapy |
| Extemporaneous tablet suspensions |
Low-cost substitute but dependent on pharmacy capability |
Qbrelis is the most relevant branded liquid ACE-inhibitor comparison because it offers a commercially manufactured oral solution rather than a tablet-based compounding approach. The products differ in active ingredient, clinical preference, dosing conventions, payer treatment, and prescriber familiarity.
EPANED can benefit when a clinician specifically wants enalapril or when a patient has a history of tolerating it. It can lose share when prescribers favor lisinopril, when payer rules prefer another product, or when pharmacies can compound enalapril at materially lower cost.
What is the financial trajectory for EPANED?
The likely financial profile is stable but limited by market size. Public filings do not provide standalone EPANED revenue, unit volume, operating margin, or cash-flow data. Product-level financial analysis must therefore rely on commercial structure rather than reported sales.
Revenue profile
EPANED has several characteristics that can support revenue per prescription:
- Liquid dosage-form premium
- Specialty pediatric positioning
- Lower direct substitution among patients who cannot swallow tablets
- Potential use in hospital and specialty-pharmacy channels
- Value from avoiding compounding labor and variability
The product also has structural revenue limits:
- Small pediatric patient population
- Mature active ingredient
- Generic tablet competition
- Compounding substitution
- Payer step edits and prior authorization
- Low likelihood of broad primary-care adoption
- Potentially limited refill duration in pediatric patients whose doses change with weight
The product is more likely to generate a durable niche revenue stream than blockbuster-scale sales. Revenue growth would depend on increasing adoption among pediatric institutions, improving reimbursement, securing dependable pharmacy distribution, and expanding use in dysphagia and feeding-tube populations.
Margin profile
A specialty oral solution can have attractive gross margins if manufacturing yields are reliable and volumes are sufficient. Net margin is more exposed to:
- Small production runs
- Packaging and dosing-device costs
- Stability testing
- Specialty distribution fees
- Patient support programs
- Payer rebates
- Returns and inventory management
- Regulatory maintenance costs
The economic model is stronger when EPANED is sold as part of a broader liquid-medication portfolio. Shared sales, regulatory, medical, and distribution infrastructure can reduce the burden assigned to each product.
Which companies are challenging EPANED commercially?
The most important competitive groups are not necessarily named generic manufacturers. They include:
- Generic tablet manufacturers supplying low-cost enalapril.
- Compounding pharmacies producing enalapril liquids.
- Manufacturers of other liquid ACE inhibitors.
- Specialty pharmaceutical companies developing pediatric dosage forms.
- Hospitals and health systems using internal compounding protocols.
The most credible commercial threat is substitution by compounded enalapril or another liquid ACE inhibitor, not a large-scale generic launch that displaces all EPANED demand. A direct generic oral-solution entrant could increase price pressure, but the market’s limited size may reduce the incentive for multiple manufacturers to enter.
What generic launch risks exist?
A direct generic oral-solution launch could produce three effects:
- Lower reimbursement benchmarks
- Greater pharmacy substitution
- Reduced negotiating leverage for the branded product
The risk is moderated by the technical requirements for liquid stability, taste, concentration uniformity, packaging, and dosing-device compatibility. These requirements can create manufacturing friction, but they are not equivalent to a strong blocking patent.
The most probable launch scenario is gradual erosion rather than an immediate collapse. Existing EPANED users may remain on the brand when clinicians value product familiarity or when a payer does not require substitution. New prescriptions are more vulnerable to lower-priced alternatives.
What is the geographic coverage of EPANED?
EPANED’s principal commercial opportunity is the United States, where its FDA-approved labeling, reimbursement systems, specialty pharmacy networks, and pediatric prescribing channels are established. International expansion would require separate regulatory filings, local distribution, pricing approval, and potentially a different product name or formulation.
Geographic expansion is unlikely to be the primary growth engine unless the product is paired with a broader pediatric cardiovascular portfolio. The commercial rationale is stronger in markets with high use of oral liquids and limited access to reliable extemporaneous compounding.
Key Takeaways
- EPANED KIT is a specialty oral-solution presentation of the mature small-molecule drug enalapril.
- Its value is concentrated in pediatric and swallowing-impaired patients.
- The core enalapril patent estate is expired, and the product does not have the protection profile of a new chemical entity.
- Formulation, manufacturing, regulatory, and brand assets may slow direct substitution but do not eliminate competition.
- No major publicly visible Paragraph IV litigation defines the product’s current market position.
- Biosimilar risk is not applicable.
- The main competitors are generic enalapril tablets, compounded enalapril liquids, Qbrelis, and other liquid cardiovascular products.
- Public sources do not disclose standalone EPANED revenue or profitability.
- The financial trajectory is most consistent with a defensible but limited specialty-product revenue stream, with erosion risk from compounding, payer restrictions, and direct liquid-formulation competition.
FAQs
Is EPANED the same as generic enalapril?
No. EPANED contains the same active ingredient, enalapril maleate, but is an FDA-approved oral solution. Generic enalapril is commonly supplied as tablets.
Can pharmacies compound an enalapril liquid instead of dispensing EPANED?
Yes. Compounding pharmacies may provide liquid preparations when clinically appropriate and legally permitted. The formulation, stability, flavor, concentration, and quality controls may differ from the branded product.
Does EPANED have pediatric exclusivity?
EPANED has pediatric-oriented utility, but pediatric use does not by itself establish permanent exclusivity. Any FDA pediatric exclusivity would depend on a specific agency award and would be time-limited.
Is EPANED protected by an Orange Book patent?
The FDA Orange Book is the controlling source for current patent listings. EPANED’s commercial profile does not indicate a broad, active patent blocking generic enalapril therapy.
Could a generic manufacturer launch a liquid equivalent to EPANED?
Potentially. A challenger would need to satisfy FDA requirements for formulation equivalence, stability, manufacturing controls, labeling, and dosing-device performance. The market opportunity may be limited by the size of the pediatric liquid segment.
References
- U.S. Food and Drug Administration. (n.d.). EPANED (enalapril maleate) oral solution prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- DailyMed. (n.d.). EPANED- enalapril maleate solution. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. NDA 207985.
- U.S. Food and Drug Administration. (n.d.). Qbrelis (lisinopril) oral solution prescribing information.
